Licensing · Global (LMICs) · Announced 19 Nov 2026
Innogen Pharmaceuticals → Arcera Life Sciences
HKEX-listed Innogen granted Abu Dhabi-based Arcera exclusive rights to commercialise its long-acting GLP-1 efsubaglutide alfa in selected Middle East (incl. UAE), African, Eastern European and Latin American markets, for an undisclosed upfront plus milestones and royalties.
Parties: Innogen Pharmaceuticals (China) → Arcera Life Sciences (United Arab Emirates)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Selected countries in the Middle East (including the UAE), Africa, Eastern Europe and Latin America; countries not listed
- Therapeutic area
- Metabolic / Diabetes
- Asset
- efsubaglutide alfa
- Announced
- 19 Nov 2026
Our analysis
Why this matters
Arcera Life Sciences and Innogen Pharmaceuticals announced on 19 November 2026 an exclusive licensing and commercialisation agreement for Efsubaglutide Alfa, Innogen's GLP-1 receptor agonist. Arcera gets the rights in selected countries across the Middle East (including the UAE), Africa, Eastern Europe and Latin America; the countries were not listed. Innogen receives an upfront payment and is eligible for milestones and tiered royalties on net sales. No amounts were disclosed. Commercialisation starts once local regulatory approvals are obtained.
Efsubaglutide Alfa is a fusion of a human GLP-1 analogue with an IgG Fc fragment. It is approved for type 2 diabetes in mainland China and Macao and is on China's National Reimbursement Drug List. Innogen reports an HbA1c reduction of about 2.2 percentage points at week 24, average weight loss of 10.6% at 18 weeks with once-weekly dosing in Chinese adults with overweight or obesity, and a Phase II study in Australia testing once-monthly dosing.
The full analysis is free to read with a work email on this page.